The DOI matches its Crossref record; 38 of the 40 references it cites were found in a registry or an index.
Evolutionary insights into coagulation factor IX Padua and other high-specific-activity variants
Open accessAbstract
The high-specific-activity factor IX (FIX) variant Padua (R338L) is the most promising transgene for hemophilia B (HB) gene therapy. Although R338 is strongly conserved in mammalian evolution, amino acid substitutions at this position are underrepresented in HB databases. We therefore undertook a complete 20 amino acid scan and determined the specific activity of human (h) and canine (c) FIX variants with every amino acid substituted at position 338. Notably, we observe that hFIX-R338L is the most active variant and cFIX-R338L is sevenfold higher than wild-type (WT) cFIX. This is consistent with the previous identification of hFIX-R338L as a cause of a rare X-linked thrombophilia risk factor. Moreover, WT hFIX and cFIX are some of the least active variants. We confirmed the increased specific activity relative to FIX-WT in vivo of a new variant, cFIX-R338I, after gene therapy in an HB dog. Last, we screened 232 pediatric subjects with thromboembolic disease without identifying F9 R338 variants. Together these observations suggest a surprising evolutionary pressure to limit FIX activity with WT FIX rather than maximize FIX activity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The naturally occurring Padua mutation represents a single amino acid change (R338L) in human FIX that results in a ~1 log increased specific activity, resulting for higher efficacy in gene therapy per FIX antigen level (28).”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [28]
Citations
Cites
Raffini, L., Huang, Y.-S., Witmer, C., & Feudtner, C. (2009) · Pediatrics · doi:10.1542/peds.2009-0768 · Cited by 825
Self-citationHemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant
George, L. A., Sullivan, S. K., Giermasz, A., Rasko, J. E. J., Samelson-Jones, B. J., Ducore, J., Cuker, A., Sullivan, L. M., Majumdar, S., Teitel, J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708538 · Cited by 762 · cited 6×
“We initially used HEK293 cells to express the FIX variants; HEK293 cells are frequently used to study FIX,6,16,17 as well as manufacturing commercial FIX products for HB.18 In this 20 amino acid scan, we find the hFIX-R338L, the previously identified thrombophilia causing Padua variant,2 has the highest specific activ…”
BackgroundSelf-citationX-Linked Thrombophilia with a Mutant Factor IX (Factor IX Padua)
Simioni, P., Tormene, D., Tognin, G., Gavasso, S., Bulato, C., Iacobelli, N. P., Finn, J. D., Spiezia, L., Radu, C., & Arruda, V. R. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904377 · Cited by 394 · cited 4×
“These results extend previous reports of FIX R338 substitutions not being identified in 1214 cumulative subjects including 767 adult patients with venous thromboembolism and 447 adult controls (supplemental Table 3).(2,26-28) Discussion Herein, we demonstrate that most amino acid substitutions at R338 in hFIX or cFIX…”
BackgroundMethodResultSelf-citationRallapalli, P. M., Kemball‐Cook, G., Tuddenham, E. G., Gomez, K., & Perkins, S. J. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12276 · Cited by 175
Inherited thrombophilia: a double-edged sword
Middeldorp, S. (2016) · Hematology · doi:10.1182/asheducation-2016.1.1 · Cited by 154
Crudele, J. M., Finn, J. D., Siner, J. I., Martin, N. B., Niemeyer, G. P., Zhou, S., Mingozzi, F., Lothrop, C. D., & Arruda, V. R. (2015) · Blood · doi:10.1182/blood-2014-07-588194 · Cited by 153
Self-citationMulticentre evaluation of combined prothrombotic defects associated with thrombophilia in childhood
Ehrenforth, S., Junker, R., Koch, H. G., Kreuz, W., Münchow, N., Scharrer, I., Nowak‐Göttl, U., & for the Childhood Thrombophilia Study Group (1999) · European Journal of Pediatrics · doi:10.1007/pl00014359 · Cited by 130
Arruda, V. R., Stedman, H. H., Haurigot, V., Buchlis, G., Baila, S., Favaro, P. M. B., Chen, Y.-F., Franck, H. W. G., Zhou, S., Wright, J. F., et al. (2010) · Blood · doi:10.1182/blood-2009-12-261156 · Cited by 120
Self-citationFinn, J. D., Nichols, T. C., Svoronos, N., Merricks, E. P., Bellenger, D. A., Zhou, S., Simioni, P., High, K. A., & Arruda, V. R. (2012) · Blood · doi:10.1182/blood-2012-06-440123 · Cited by 117 · cited 3×
“Here, we compare the cFIX-specific activity of cFIX-R338I with our previous published experience with cFIX-WT (R338)(12) and cFIXR338L.(14) We used that same AAV expression cassette (supplemental Figure 3A), vector dose (3 3 10(12) vg/kg), delivery method F 0 5 10 15 humna FIX A”
BackgroundMethodSelf-citationMonahan, P. E., Sun, J., Gui, T., Hu, G., Hannah, W. B., Wichlan, D. G., Wu, Z., Grieger, J. C., Li, C., Suwanmanee, T., et al. (2015) · Human Gene Therapy · doi:10.1089/hum.2014.106 · Cited by 108 · cited 2×
“We observe the specific activity of hFIX-R338A is fivefold higher than FIX-WT, consistent with previous in vitro(6,29,30) and in vivo gene therapy studies.(7,31) Likewise, hFIX-R338Q has intermediate specific activity between hFIX-WT and hFIX-R338L, as has been observed previously in vitro(32) and in vivo gene therapy…”
Result
Cited by
Berntorp, E., Fischer, K., Hart, D. P., Mancuso, M. E., Stephensen, D., Shapiro, A. D., & Blanchette, V. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00278-x · Cited by 328
Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy
Bertolini, T. B., Shirley, J. L., Zolotukhin, I., Li, X., Kaisho, T., Xiao, W., Kumar, S. R. P., & Herzog, R. W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.672449 · Cited by 80
“The naturally occurring Padua mutation represents a single amino acid change (R338L) in human FIX that results in a ~1 log increased specific activity, resulting for higher efficacy in gene therapy per FIX antigen level (28).”
BackgroundGene Therapy in Hemophilia: Recent Advances
Rodriguez-Merchan, E. C., Pablo-Moreno, J. A. D., & Liras, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147647 · Cited by 65
“in dogs with HB [78] confirmed an increased specific in vivo activity of FIX-R338L as compared with FIX-WT following gene therapy with AAV6.”
BackgroundThe More Recent History of Hemophilia Treatment
Franchini, M., & Mannucci, P. M. (2022) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0042-1756188 · Cited by 58
Childers, K. C., Peters, S. C., & Spiegel, P. C. (2022) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15793 · Cited by 48
Metadata
- Authors
- Samelson-Jones, B. J., Finn, J. D., Raffini, L. J., Merricks, E. P., Camire, R. M., Nichols, T. C., & Arruda, V. R.
- Affiliations
- Divsion of Hematology, The Children's Hospital of Philadelphia, Philadelphia, PA;
- Children's Hospital of Philadelphia (US)
- University of North Carolina at Chapel Hill (US)
- ORCID
- Venue
- Blood Advances
- Publisher
- American Society of Hematology
- Published
- 2021-03-03
- Volume
- 5
- Issue
- 5
- Pages
- 1324-1332
- ISSN
- 2473-9529 (ISSN-L)
- 2473-9537
- PMC
- PMC7948292
- OpenAlex
- W3134932784
- Cited by
- 31
- References
- 40
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 6 · 2023: 2 · 2022: 6 · 2021: 4
- FWCI
- 2.93
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Blood Advances (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Blood Foundation
- National Heart, Lung, and Blood Institute (K08HL140078, P01HL064190, P01HL139420)
- Topics
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Keywords
- coagulation factor IX, hemophilia B, gene therapy, canine model, specific activity, evolutionary conservation, thromboembolism, pediatric patients
- MeSH terms
- Animals, Blood Coagulation, Blood Coagulation Tests, Child, Hemophilia B, Dogs, Factor IX, Humans, Genetic Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evolutionary insights into coagulation factor IX Padua and other high-specific-activity variants. https://app.cochat.ai/papers/10.1182/bloodadvances.2019000405
- The paper
- Samelson-Jones, B. J., Finn, J. D., Raffini, L. J., Merricks, E. P., Camire, R. M., Nichols, T. C., & Arruda, V. R. (2021). Evolutionary insights into coagulation factor IX Padua and other high-specific-activity variants. Blood Advances. https://doi.org/10.1182/bloodadvances.2019000405
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.